NCT06535854ClinicalTrials.gov
Prevail Global Study
A Randomized Controlled Study of the Prevail Drug-Coated Balloon in Subjects With In-stent Restenosis and a Single Arm Prospectively Enrolled Study of the Prevail Drug-Coated Balloon for de Novo Lesions in Small Vessel Disease (Prevail Global).
Kurz gefasst
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
Interventionell1.205 Teilnehmende gesucht79 Studienzentren9 Länder
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT06535854Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 4 Wochen
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2024-08-02; recorded start 2025-02-24
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 10 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Vascular)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding7/20
Single-blind
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 51 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 1,205 participants (target), run at 79 sites, across 9 countries.
How this score is built
- Enrolment31/40
1,205 participants (target)
- Site count20/25
51 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 72 months
- Sponsor scale3/10
Medtronic Vascular has led 11 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
Erkrankungen
- Coronary Artery Disease
Eignung
| Geschlecht | Alle |
|---|---|
| Alter | 18 Years – Kein Höchstalter |
| Gesunde Freiwillige | Nein |
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Interventionell |
|---|---|
| Phase | Nicht zutreffend |
| Zuteilung | Randomisiert |
| Interventionsmodell | PARALLEL |
| Primäres Ziel | TREATMENT |
| Verblindung | SINGLE (1) |
| Teilnahme | 1.205 Teilnehmende gesucht |
Sponsor und Mitwirkende
- Medtronic Vascular Sponsor
Studienarme und Interventionen
- ISR Cohort Prevail DCBEXPERIMENTAL
To evaluate the clinical safety and efficacy of the Prevail DCB in the treatment of ISR with coronary lesions previously treated with drug-eluting or bare metal stents in native coronary arteries.
- DNSV Cohort (RVD 2.0 - 2.75mm)EXPERIMENTAL
To evaluate the clinical safety and efficacy of the Prevail DCB as compared to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease.
Interventionen
- Medizinprodukt Agent DCB
The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
- Medizinprodukt Prevail DCB
The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.
Endpunkte
Primärer Endpunkt
ISR Cohort Primary Analysis
The TLF rate of the Prevail DCB arm at 12 months post procedure compared to the Agent DCB arm for non-inferiority
Zeitrahmen 1 year post-procedure
Primärer Endpunkt
DNSV Cohort Primary Analysis
The TLF rate of the Prevail DCB arm at 12 months post procedure compared to a DES historical control
Zeitrahmen 1 year post-procedure
Sekundärer Endpunkt
Acute success
Acute success (device, lesion, and procedure) through hospital discharge only
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Sekundärer Endpunkt
All deaths
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Sekundärer Endpunkt
Cardiac death
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Sekundärer Endpunkt
All myocardial infarction (MI), including target vessel myocardial infarction (TVMI)
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Sekundärer Endpunkt
Clinically-driven target lesion revascularization (cd-TLR) defined as repeat PCI or CABG to the target lesion
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Sekundärer Endpunkt
Clinically-driven target vessel revascularization (cd-TVR)
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Sekundärer Endpunkt
Major adverse cardiac event (MACE) defined as composite of death, MI, or repeat cd-TLR
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Sekundärer Endpunkt
Target lesion failure (TLF) defined as composite of cardiac death, TVMI, or cd-TLR
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Sekundärer Endpunkt
Target vessel failure (TVF) defined as composite of cardiac death, TVMI, or cd-TVR
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Sekundärer Endpunkt
Target lesion thrombosis (TLT) (definite or probable) according to Academic Research Consortium (ARC) definition
Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Daten
| Startdatum | 24. Februar 2025 (tatsächlich) |
|---|---|
| Primärer Abschluss | 1. Februar 2027 (geschätzt) |
| Abschluss | 1. Februar 2031 (geschätzt) |
| Erstveröffentlichung | 2. August 2024 (tatsächlich) |
| Zuletzt aktualisiert | 21. Oktober 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | Oktober 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
78 Studienzentren rekrutieren
Canada
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Montreal Heart Institute | Montreal | Rekrutiert | |
| Hôpital du Sacre Coeur de Montreal | Montreal | Rekrutiert | |
| University of Ottawa Heart Institute | Ottawa | Rekrutiert | |
| Toronto General Hospital | Toronto | Rekrutiert | |
| Vancouver General Hospital | Vancouver | Rekrutiert |
Germany
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Herzzentrum Dresden GmbH Universitätsklinik | Dresden | Rekrutiert | |
| Universitat des Saarlandes | Homburg | Rekrutiert | |
| MediClin Herzzentrum Lahr / Baden | Lahr | Rekrutiert |
Hong Kong
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Queen Mary Hospital | Hong Kong | Rekrutiert |
Ireland
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Mater Private Network | Dublin | Rekrutiert | |
| Galway University Hospitals - University Hospital Galway (UHG) | Galway | Rekrutiert |
Japan
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Teikyo University Hospital | Itabashi-ku | Tokyo | Rekrutiert |
| Shonan Kamakura General Hospital | Kamakura | Kanagawa | Rekrutiert |
| Kokura Memorial Hospital | Kitakyushu | Fukuoka | Rekrutiert |
| Sendai Kousei Hospital | Sendai | Miyagi | Rekrutiert |
| Saiseikai Yokohamashi Tobu Hospital | Yokohama | Kanagawa | Rekrutiert |
Singapore
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Sengkang General Hospital | Singapore | Rekrutiert | |
| Tan Tock Seng Hospital | Singapore | Rekrutiert |
South Korea
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Keimyung University Dongsan Hospital | Daegu | Rekrutiert | |
| Korea University Anam Hospital | Seoul | Rekrutiert | |
| Seoul Saint Marys Hospital | Seoul | Rekrutiert | |
| Seoul National University Hospital | Seoul | Rekrutiert | |
| Asan Medical Center | Seoul | Rekrutiert |
United Kingdom
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital | Newcastle upon Tyne | Rekrutiert |
United States
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Lehigh Valley Hospital - Cedar Crest | Allentown | Pennsylvania | Rekrutiert |
| AnMed Health Medical Center | Anderson | South Carolina | Rekrutiert |
| University of Michigan Health System - University Hospital | Ann Arbor | Michigan | Rekrutiert |
| Emory University Hospital Midtown | Atlanta | Georgia | Rekrutiert |
| Piedmont Atlanta Hospital | Atlanta | Georgia | Rekrutiert |
| The University of Alabama at Birmingham | Birmingham | Alabama | Rekrutiert |
| Cardiology P.C. | Birmingham | Alabama | Rekrutiert |
| Kaleida Health | Buffalo | New York | Rekrutiert |
| Virtua Our Lady of Lourdes Hospital | Camden | New Jersey | Rekrutiert |
| Medical University of South Carolina (MUSC) | Charleston | South Carolina | Rekrutiert |
| Advocate Illinois Masonic Medical Center | Chicago | Illinois | Rekrutiert |
| The Lindner Research Center | Cincinnati | Ohio | Rekrutiert |
| BayCare Health System | Clearwater | Florida | Rekrutiert |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | Rekrutiert |
| OhioHealth Riverside Methodist Hospital | Columbus | Ohio | Rekrutiert |
| Baylor Heart & Vascular Hospital | Dallas | Texas | Rekrutiert |
| Saint Elizabeth Healthcare | Edgewood | Kentucky | Rekrutiert |
| M Health Fairview Clinic | Edina | Minnesota | Zurückgezogen |
| Parkview Health | Fort Wayne | Indiana | Rekrutiert |
| North Florida Regional Medical Center | Gainesville | Florida | Rekrutiert |
| Corewell Health | Grand Rapids | Michigan | Rekrutiert |
| The Moses H Cone Memorial Hospital | Greensboro | North Carolina | Rekrutiert |
| UPMC Pinnacle Harrisburg Campus | Harrisburg | Pennsylvania | Rekrutiert |
| HCA Houston Medical Center | Houston | Texas | Rekrutiert |
| Huntsville Hospital | Huntsville | Alabama | Rekrutiert |
| Saint Lukes Mid America Heart Institute | Kansas City | Missouri | Rekrutiert |
29 weitere Studienzentren sind im Registereintrag aufgeführt.
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
- 21. Oktober 2026
Studienzentrum hinzugefügt
28 sites added (79 total)
5179